Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients
Open Access
- 27 July 2006
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 17 (11) , 1665-1672
- https://doi.org/10.1093/annonc/mdl174
Abstract
Background: In advanced gastric cancer, the relationship between tumor response and prognosis is far from clear. Methods: We performed a pooled analysis on published data from 4593 patients in 25 randomized trials of first-line chemotherapy for advanced gastric cancer. A weighed analysis was used to investigate the correlation between objective response rate (RR) and time to progression (TTP) and overall survival time (OS). Results: A moderate correlation was found between RR and TTP and OS (r = 0.49 and r = 0.45, respectively) in all 25 trials. In treatment arms without new drugs including irinotecan, taxanes, or oxaliplatin, RR also was associated with TTP and OS (r = 0.56 and r = 0.47, respectively). However, no association between RR and OS was found, whereas there was a moderate correlation between RR and TTP (r = 0.41) in treatment arms using new drugs. Conclusions: Our results indicated that response to treatment was related to TTP and OS. The potential role of objective response as a surrogate in chemotherapy trials of advanced gastric cancer warrants further investigation, especially with regard to treatment with new drugs.Keywords
This publication has 42 references indexed in Scilit:
- Evolving Chemotherapy for Advanced Gastric CancerThe Oncologist, 2005
- Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Randomized phase 3 trial of irinotecan (CPT-11) + 5FU/folinic acid (FA) vs CDDP + 5FU in 1st-line advanced gastric cancer patientsJournal of Clinical Oncology, 2005
- Current status and future prospects of chemotherapy for metastatic gastric cancer: a reviewGastric Cancer, 2005
- Randomized Phase III Trial of Fluorouracil Alone Versus Fluorouracil Plus Cisplatin Versus Uracil and Tegafur Plus Mitomycin in Patients With Unresectable, Advanced Gastric Cancer: The Japan Clinical Oncology Group Study (JCOG9205)Journal of Clinical Oncology, 2003
- Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysisThe Lancet, 2000
- Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancerAnnals of Oncology, 1997
- Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancerBritish Journal of Cancer, 1995
- Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancerCancer, 1993
- A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancerCancer, 1993